Mirum PharmaceuticalsMEX:MIRM 46 Days Payable is 109.29 as of Mar. 2026, which is 75% above its 10-year median of 62.49. GuruFocus rates MEX:MIRM with a GF Score™ of 46/100 and a GF Value™ of MXN812.06. The stock has 5 warning signs investors should review. Among 701 Biotechnology companies, Mirum Pharmaceuticals ranks worse than 58.35% on this metric.
Mirum Pharmaceuticals Days Payable Historical Data
* Premium members only.
The historical data trend for Mirum Pharmaceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MIRM vs RYTM, SYRE, PTGX: Days Payable Comparison
For the Biotechnology subindustry, Mirum Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mirum Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Mirum Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Mirum Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirum Pharmaceuticals (MEX:MIRM) has a Days Payable of 109.29 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mirum Pharmaceuticals and its competitors. This is 75% above median its historical median of 62.49. Over the past decade, Mirum Pharmaceuticals' Days Payable has ranged from 44.12 to 1,181.22. According to the industry distribution chart, Mirum Pharmaceuticals ranks #409 out of 701 companies in the Biotechnology industry, placing it in the top 58.3%.
Is Mirum Pharmaceuticals' Days Payable too high?
Mirum Pharmaceuticals' current Days Payable of 109.29 is 75% above median its 10-year median of 62.49. Over the past 10 years, this metric has ranged from a low of 44.12 to a high of 1,181.22. The Biotechnology industry median Days Payable is 112.84. Mirum Pharmaceuticals' value of 109.29 is 3.1% below this industry median. Based on the distribution chart, Mirum Pharmaceuticals ranks #409 out of 701 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Mirum Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Days Payable compare to RYTM and SYRE?
According to the Biotechnology industry distribution chart, Mirum Pharmaceuticals ranks #409 out of 701 companies for Days Payable. This places Mirum Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 112.84. Mirum Pharmaceuticals' value of 109.29 is 3.1% below this benchmark. Historically, Mirum Pharmaceuticals' own Days Payable has ranged from 44.12 to 1,181.22 over the past decade. While the company's 10-year median is 62.49 vs. the industry median of 112.84, Mirum Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mirum Pharmaceuticals's current Days Payable of 109.29 is 3.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mirum Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mirum Pharmaceuticals's current Days Payable is 109.29, which is 75% above median its own 10-year median of 62.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current Days Payable of 109.29. The stock's GF Value™ is MXN812.06, compared to a current price of MXN1,256.12 — trading 54.7% above its estimated fair value. The current Days Payable is 109.29, which is 75% above median its 10-year median of 62.49 and 3.1% below the Biotechnology industry median of 112.84. Mirum Pharmaceuticals' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current Days Payable is 109.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?
Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,256.12 is trading 54.7% above its estimated GF Value™ of MXN812.06.
Key valuation signals for MEX:MIRM:
Days Payable: 109.29 (75% above median its 10-year median of 62.49)
GF Value™: MXN812.06 vs. price of MXN1,256.12 (54.7% above fair value)
Industry Position: 3.1% below the Biotechnology median (#409 of 701)
No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
46GF Score
Get the complete analysis for MEX:MIRM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MIRM has been successfully added to your 
